Verdict: BF Biosciences Limited (PSX: BFBIO) delivered a powerful FY2026 expansion, with revenue up 62% and gross margin widening by four percentage points as Line II and new products lifted volumes and factory absorption. The quality of that growth was mixed below gross profit: selling and distribution spend almost doubled, net margin narrowed, and a Rs1.34 billion inventory build pushed operating cash flow slightly negative. This is a credible scale-up year, but the next test is turning the enlarged product platform and stock position into cash without giving back the margin gains.
Results at a glance
- Reporting basis: audited standalone financial statements for the year ended 30 June 2026; figures below are in Pakistani rupees unless stated otherwise.
- Net revenue: Rs9.46 billion, up 62.1% from Rs5.84 billion.
- Gross profit: Rs4.09 billion, up 78.7%; gross margin expanded to 43.2% from 39.2%.
- Profit from operations: Rs1.17 billion, up 37.8%, while operating margin eased to 12.4% from 14.6%.
- Profit before minimum/final tax and income tax: Rs1.07 billion, up 47.5%. Profit after tax: Rs632.1 million, up 41.4%.
- Basic and diluted EPS: Rs7.16 versus Rs5.52. EPS growth of 30% lagged profit growth because the IPO shares were included for the full current year but only part of the prior-year weighted average.
- Cash: operating activities used Rs26.5 million versus generating Rs299.8 million in FY2025. Fixed capital expenditure was Rs603.1 million.
- Dividend: nil. The board said cash is being retained for expansion.
AlphaGen model scores
These are AlphaGen model outputs, not figures reported by the company and not investment advice.
- Alpha QoQ Score: 64.26
- TTM Performance Score: 77.50
- 3Y Business Perf Score: 63.27
- Sector Leadership Score: 62.06
What improved
The most important positive is that growth was operational rather than dependent on financial income or a one-off gain. Management said in-market generic sales rose 61% and institutional sales increased 69%. It attributed the advance mainly to volumes from existing and newly launched products after Line II began commercial operations. That explanation is consistent with the income statement: net revenue added Rs3.62 billion year on year, while other income actually declined to Rs106.8 million from Rs125.9 million.
The mix and utilization effect was visible at gross-profit level. Cost of sales rose 51.4%, slower than revenue, so gross profit increased 78.7%. Gross margin improved by about 401 basis points to 43.2%. Management linked the change to a better sales mix, improved capacity utilization and stronger absorption of factory overheads. Raw and packing materials consumed rose to Rs3.03 billion from Rs1.72 billion, while fuel and power reached Rs324.6 million from Rs269.6 million. The company therefore absorbed substantially higher manufacturing inputs while still widening the gross spread.
Financing pressure also eased. Finance cost declined 17.0% to Rs106.0 million, including lower conventional long-term loan mark-up. Total interest-bearing debt, including musharaka and current maturities, fell about 6% to roughly Rs1.61 billion. Net debt remained around Rs1.35 billion because cash balances also declined, but the direction of gross borrowings and finance cost was favorable.
The year also extended a multi-year revenue expansion. The annual report shows net revenue rising from Rs1.81 billion in FY2023 to Rs3.66 billion in FY2024, Rs5.84 billion in FY2025 and Rs9.46 billion in FY2026. Profit after tax increased from Rs149 million in FY2023 to Rs385 million, Rs447 million and Rs632 million over the same sequence. That record confirms the scale-up is larger than a single-period fluctuation, although margins have not advanced in a straight line.
What weakened / needs attention
Commercial investment consumed a large part of the gross-profit improvement. Selling and distribution expense surged 86.9% to Rs2.70 billion. The largest components were staff costs of Rs952.7 million, conferences, seminars and training of Rs691.9 million, sales promotion of Rs364.6 million, and travel and transport of Rs446.2 million. Management described the rise as field-force expansion, higher marketing activity and inflationary pressure to support new products. This may be growth investment, but it is already material: selling and distribution absorbed 28.6% of revenue, up from 24.8%.
Administrative expense more than tripled to Rs202.5 million from Rs60.6 million, primarily through higher headcount and support costs. Together, commercial and administrative spending explains why operating profit grew 37.8%, well below the 78.7% increase in gross profit. Operating margin compressed by about 218 basis points to 12.4%. The filing says these ratios are expected to normalize, but that is management's expectation rather than an achieved result.
The tax line was another drag. Profit before minimum/final tax and income tax was Rs1.07 billion; after a Rs10.6 million minimum/final-tax charge and Rs424.6 million income-tax expense, profit after tax was Rs632.1 million. The effective burden was therefore high enough that net margin slipped to 6.7% from 7.7%, despite the stronger gross margin and lower finance cost.
Cash conversion was the clearest weakness. Cash generated before working-capital changes was Rs1.49 billion, but working capital absorbed Rs1.14 billion net. Stock in trade alone consumed Rs1.34 billion, while trade debts and loans/advances used another Rs302.8 million. A Rs454.7 million increase in trade payables and contract liabilities only partly offset those uses. After taxes and statutory fund payments, operating cash flow was negative Rs26.5 million.
The balance sheet tells the same story. Stock in trade rose 78.6% to Rs2.94 billion and trade debts rose 89.7% to Rs349.5 million. Current liabilities increased 42.0% to Rs2.31 billion, faster than the 15.9% rise in current assets, reducing the current ratio to about 1.9 times from 2.4 times. The quick ratio was only 0.6 times because inventory represented roughly two-thirds of current assets. Closing inventory equaled about 31.1% of annual revenue, up from 28.2%, while closing trade debts equaled 3.7% versus 3.2%. These are balance-date indicators, not turnover ratios, but they reinforce the direction of the cash-flow evidence. None of this proves excess or obsolete stock; the filing records provisions and net-realizable-value adjustments. It does mean the inventory build must be monitored against sales, collections and launch requirements.
Capital allocation and funding
BFBIO invested Rs603.1 million in fixed capital during FY2026, up from Rs324.4 million. Operating cash flow less this capital expenditure was approximately negative Rs630 million; this is a simple analytical subtraction, not a company-reported free-cash-flow measure. The company funded the year partly by redeeming short-term investments: those investments fell to Rs311.1 million from Rs1.17 billion, while cash and bank balances declined 24% to Rs261.7 million.
The IPO proceeds note provides useful accountability. Of Rs1.855 billion net proceeds, Rs530.8 million had been used for plant and machinery, Rs84.3 million for certifications and new-product development, and Rs1.017 billion for working capital by 30 June 2026. The unutilized balance was Rs223.6 million. Retaining earnings rather than paying a dividend is consistent with this expansion program, but shareholders should judge the decision by future cash generation and returns on the enlarged asset base.
The balance sheet is not highly levered relative to the growth investment. Equity increased 13.6% to Rs5.29 billion, supported by retained profit, while total debt declined. Gearing reported by the company fell to 24.4% from 31.3%. The risk is therefore less about an immediate debt spiral and more about whether inventory, commercial spending and capital projects produce durable earnings and cash returns.
Product and geographic context
BFBIO remains a single reportable pharmaceutical segment and overwhelmingly domestic: Pakistan generated 98.44% of FY2026 revenue. Export revenue was only Rs147.5 million before deductions, although sales reached Nepal, Cambodia, Uzbekistan, Kenya, Afghanistan and several smaller markets. Management warned that the Pakistan-Afghanistan border closure was already hurting exports after year-end. Given the small export base, this is more relevant to the pace of diversification than to the FY2026 earnings core.
Management highlighted Sematide (semaglutide), Zeptide (tirzepatide) and Ferulin (human insulin) among the new launches supporting growth. It also said production of Ferulin cartridges and Insulin Glargine under the Meritus brand began after year-end, with commercial launches planned for early October 2026. Additional cartridge and pre-filled-syringe presentations, plus work toward stringent-regulatory-authority certification, could broaden the platform. These are opportunities, not booked FY2026 earnings, and execution should be tested against disclosed sales, margin and working-capital outcomes.
The company also identifies imported raw materials, currency volatility, pharmaceutical pricing controls, energy costs, regulatory requirements and supply-chain disruption as material risks. The filing does not quantify the sensitivity of FY2026 earnings to exchange rates, price changes or individual product volumes, so it would be speculative to assign precise profit contributions beyond management's disclosed volume, mix and utilization explanation.
What to monitor next
- Inventory conversion: whether stock growth slows and operating cash flow turns sustainably positive.
- Commercial efficiency: whether selling and distribution expense grows more slowly than revenue after the field-force and launch build-out.
- Gross-margin durability: whether the 43.2% margin holds as product mix changes and imported-input costs fluctuate.
- New-product execution: disclosed sales traction for insulin cartridges, Insulin Glargine and the metabolic-care portfolio rather than launch announcements alone.
- Return on expansion: utilization of the remaining IPO proceeds, completion of committed investments and returns on the Rs603 million FY2026 capital spend.
- Liquidity mix: the current and quick ratios, short-term borrowing, and the balance between inventory, cash and marketable investments.
- Dividend capacity: the board's willingness to distribute cash only after expansion and working-capital needs are funded internally.
Evidence and limitations
The core result is supported by the audited standalone annual statements and an unmodified KPMG audit opinion. The article uses the company's reported FY2026 and FY2025 figures and management's stated operating explanations. BFBIO does not disclose production capacity because its multi-product facility has varying processes, and it does not provide a product-level profit bridge. Accordingly, no unsupported attribution has been made for pricing, individual brands or unit economics. Quarterly cash conversion is not discussed because the audited filing supplies annual cash flow rather than a discrete fourth-quarter cash-flow statement.